{"id":292432,"date":"2026-10-07T13:32:18","date_gmt":"2026-10-07T08:02:18","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=292432"},"modified":"2026-10-07T13:32:18","modified_gmt":"2026-10-07T08:02:18","slug":"injectable-and-contract-formulation-stocks-strong-roadmap","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/injectable-and-contract-formulation-stocks-strong-roadmap\/","title":{"rendered":"3 Injectable and Contract Formulation Stocks With a Strong Future Roadmap: Caplin Point Laboratories, Venus Remedies and Syncom Formulations (India)"},"content":{"rendered":"

Caplin Point Rs 2,679.70, P\/E 30.04. Venus Remedies Rs 1,746.70, P\/E 20.46. Syncom Formulations Rs 23.22, P\/E 25.54. Closing prices of 6 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Injectable and contract formulation stocks with the clearest long-term roadmaps today include Caplin Point Laboratories in injectable and generic formulations for Latin America and other markets, Venus Remedies in injectables and critical care medicines and Syncom Formulations (India) in contract manufacturing of formulations. FY26 revenue growth was 13.2% at Caplin Point, 16.9% at Venus Remedies and 7.9% at Syncom Formulations. P\/E stands at 30.04 for Caplin Point (industry 37.19), 20.46 for Venus Remedies (industry 37.19) and 25.54 for Syncom Formulations (industry 37.19). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Injectable and contract formulation stocks give investors exposure to smaller drug makers that supply injectables and make medicines for other pharma firms. Results depend on approvals, pricing and plant compliance, which is why margins and execution matter as much as headline growth.<\/p>\n

This list covers three small pharma formulation stocks: Caplin Point Laboratories for injectable and generic formulations for Latin America and other markets, Venus Remedies for injectables and critical care medicines and Syncom Formulations (India) for contract manufacturing of formulations. Every figure comes from the latest reported financials and the 6 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n